Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / People / Mark A. Goldsmith
Person

Mark A. Goldsmith

Tracked across 2 events · 14 articles · First seen Apr 15, 2026 · Last active Aug 11, 2026

Sentiment
20
Attention
4
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
4 0
Regulatory
EMA phased review of daraxonrasib
Impact: Mark A. Goldsmith is CEO and chairman of Revolution Medicines; he commented on the regulatory progress, expressing optimism about global availability.
Jul 07, 2026 · 7 articles
4 40
Business
BeOne and Revolution Medicines oncology collaboration
BeOne Medicines and Revolution Medicines announced a multi-part collaboration on August 10, 2026. The deal includes a clinical collaboration to evaluate drug combinations combining select BeOne oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors…
Impact: As CEO of Revolution Medicines, Goldsmith highlights the strategic value of the collaboration in advancing RAS(ON) inhibitors globally.
Aug 10, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Mark A. Goldsmith live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.